@article {7716,
	title = {Multiple myeloma treatment strategies with novel agents in 2011: A European perspective},
	journal = {Oncologist},
	volume = {16},
	year = {2011},
	note = {Cited By :26Export Date: 21 February 2017},
	month = {2011},
	pages = {388 - 403},
	abstract = {The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. {\textcopyright} AlphaMed Press.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955552589\&doi=10.1634\%2ftheoncologist.2010-0386\&partnerID=40\&md5=42f1373ea93eb857e59d02def01201fc},
	author = {Ludwig, H. and Beksac, M. and Blad{\'e}, J. and Cavenagh, J. and Cavo, M. and Delforge, M. and Dimopoulos, M. and Drach, J. and Einsele, H. and Facon, T. and Goldschmidt, H. and Harousseau, J.-L. and Hess, U. and Kropff, M. and Da Costa, F.L. and Louw, V. and Magen-Nativ, H. and Mendeleeva, L. and Nahi, H. and Plesner, T. and San-Miguel, J. and Sonneveld, P. and Udvardy, M. and Sondergeld, P. and Palumbo, A.}
}
